News and Media
Press Releases
Bloom Science Announces Positive Topline Data from a Phase 1 Clinical Trial of BL-001, a Potential First-in-Class Therapeutic Being Developed for Both Dravet Syndrome and ALS
Bloom Science Announces Positive Topline Data from a Phase 1 Clinical Trial of BL-001, a Potential First-in-Class Therapeutic Being Developed for Both Dravet Syndrome and ALS BL-001...
Bloom Science Names Top Biotechnology Executive, Dr. Grace E. Colón, Board Chair
Bloom Science Names Top Biotechnology Executive, Dr. Grace E. Colón, Board Chair SAN DIEGO, May 17, 2023 – Bloom Science, Inc., a clinical-stage, central nervous system (CNS) company focused...
Bloom Science Completes Enrollment in Phase 1 Trial of BL-001, a First-in-Class Therapy Being Developed for Dravet Syndrome
Bloom Science Completes Enrollment in Phase 1 Trial of BL-001, a First-in-Class Therapy Being Developed for Dravet Syndrome BL-001 Designed to Replicate the Antiepileptic Effects of the Ketogenic...
Roya Hakimzadeh Joins Bloom Science as Director of Patient Advocacy
Bloom is excited to welcome Roya Hakimzadeh as Director of Patient Advocacy. Roya joins Bloom with nearly a decade of experience working in rare disease at companies spanning development of small...
Bloom Science Appoints Medicine Development Expert Dr. Stephen Wright to Clinical Advisory Board
SAN DIEGO, Calif., January 4, 2023 -- Dr. Stephen Wright joins Bloom Science, Inc., a clinical-stage biotechnology company developing novel medicines for neurological diseases and conditions, as a...
Bloom Science to Develop ALS Biotherapeutics with Exclusive Technology License from Yeda, the Technology Transfer Company of Weizmann Institute of Science
SAN DIEGO, Calif., January 4, 2023 -- Bloom Science, Inc., a clinical-stage biotechnology company developing novel medicines for neurological diseases and conditions, and Yeda Research and...
Bloom Science Completes Successful Pre-IND Meeting with the FDA for BL-001 Clinical Trial to Treat Dravet Syndrome
SAN DIEGO, Calif., January 4, 2023 -- Bloom Science, Inc., a clinical-stage biotechnology company developing novel medicines for neurological diseases and conditions, successfully completed a...
Bloom Science to Present Live at Biotech Showcase 2023
SAN DIEGO, Calif., December 17, 2022 -- Bloom Science, Inc. founder & CEO Christopher Reyes, PhD presents live at Biotech Showcase™ 2023 on Tuesday January 10 at 2:45 p.m. PT. Biotech Showcase,...
Harnessing the Gut–Immune–Brain Axis to Treat Disease
How a 100-year-old study spawned a novel class of multifunctional neurological treatments. Read the latest on Bloom Science's epilepsy and ALS lead programs and how a 100-year-old study spawned a...
Bloom Science Raises USD $12 Million in Series A Financing
Bloom Science is developing novel engineered and rationally selected microbiome-based treatments for neurological and inflammatory diseases with initial programs in Drug Resistant Epilepsy and...
The ALS Association Awards Bloom Science to Develop Novel Gut Microbiota-based Therapies for Amyotrophic Lateral Sclerosis
Bloom Science, a biopharmaceutical company focused on the discovery and development of medicines tailored for individual patients living with neurological diseases, has received a $500,000 grant...
Bloom Science Launches to Develop Neuroprotective Epilepsy Treatments in Orphan Indications with Exclusive Technology License from UCLA
Study published in Cell demonstrates causal link between seizure susceptibility and the microbiome, identifies gut bacteria that confer anti-seizure effects Bloom Science, a biotechnology company...